Researcher

    Anne-Marie Laberge , M.D. , Ph.D.

    anne-marie.laberge.hsj@ssss.gouv.qc.ca
    Anne-Marie Laberge
    Research Axis
    Metabolic Health and Complex Diseases
    Research Theme
    Genetic and metabolic diseases in Quebec: diagnosis, mechanisms and interventions
    Address
    CHUSJ

    Phone
    514 345-4931 #4727

    Fax
    514 345-4766

    Title

    • Researcher, CHU Sainte-Justine Research Center, 2008.

    Education

    • PhD, Institute for Public Health Genetics, University of Washington, 2008.
    • Masters in Public Health, Institute for Public Health Genetics, University of Washington, 2005.
    • Fellow in Medical Genetics, Royal College of Physicians and Surgeons of Canada, 2003.
    • Specialization in Medical Genetics, University of Montreal, 2003.
    • MD, University of Montreal, 1998.

    Research Interests

    In my future research, I am particularly interested in the use of genetic technologies and services real-life settings, in their impact on health outcomes and resources, as well as in the broader health policy, legal, and ethical implications of their use. In recent years, genetic research had produced huge amounts of knowledge about associations between genetic variants and disease. As new genetic tests and services become available for clinical practice, it is important to evaluate their clinical utility. My multidisciplinary training enables me to examine these questions using different methods, both quantitative and qualitative.

    I plan to pursue the work I started during my doctoral dissertation, on the clinical use of the genetic test for Factor V Leiden, a genetic risk factor for venous thrombo-embolism and fetal loss. I plan to study the use of other genetic tests commonly used in clinical practice, particularly in the investigation of children with developmental delay and congenital deafness.

    I also have a continued interest in genetic diseases with particularities in the French Canadian population, as well as the implications these particularities can have for the use of available genetic tests in the context of population screening strategies.

    Awards and Distinctions

    • Top Scholar Award, University of Washington Graduate School, 2005.

    Presentations

    • Practice guidelines and uptake of genetic testing for Factor V Leiden. Pre-conference workshop titled Supporting Policy Development in Genetics/Genomics: Where HTA, HSR, Public Health and ELSI Research Meet. 5th Annual Meeting of Health Technology Assessment International (HTAi), Montréal, July 6, 2008.
    • Clinical Practice Guidelines about FVL Testing: Their Intended Purpose in Practice and Their Role in Defining the Standard of Care. Leducq International Network Against Thrombosis (LINAT) Annual Meeting, Oklahoma City, Oklahoma, May 30, 2008.
    • Effets fondateurs et leur impact sur la distribution des maladies génétiques au Québec. Congrès annuel de la Société québécoise de biologie clinique, Pointe-au-Pic, Québec, October 5, 2006.
    • Principaux éléments contribuant au succès d’un programme de dépistage de porteurs : regards sur quelques expériences clés. Journées annuelles de santé publique, Québec, November 17, 2005.

Publications

Cost effectiveness of newborn screening for cystic fibrosis: A simulation study - Nshimyumukiza L, Bois A, Daigneault P, Lands L, Laberge AM, Fournier D, Duplantie J, Giguere Y, Gekas J, Gagné C, Rousseau F, Reinharz D. Cost effectiveness of newborn screening for cystic fibrosis: A simulation study
. J Cystic Fibrosis 2014; 15(1): 34-45.

Genetics in health care: an overview of current and emerging models - Battista R, Blancquaert I, Laberge AM, van Schendel N, Leduc N. Genetics in health care: an overview of current and emerging models. Pub Health Genomics 2012; 15(1): 34-45.

That personal touch - Laberge AM. That personal touch. Hastings Cent Rep 2011; 41(3): 4-5.

Integrating genetic tests into clinical practice: The role of guidelines - Laberge AM, Burke W. Integrating genetic tests into clinical practice: The role of guidelines. Dans: Burke W, Edwards KA, Goering S, Holland S, Trinidad S (eds). Achieving Justice in Genomic Translation: Re-Thinking the Pathway to Benefit. New York. Oxford University Press, 2011; 112-130.

Assessing the potential success of cystic fibrosis carrier screening: Lessons learned from Tay-Sachs disease and beta-thalassemia - Laberge AM, Watts C, Porter K, Burke W. Assessing the potential success of cystic fibrosis carrier screening: Lessons learned from Tay-Sachs disease and beta-thalassemia. Pub Health Genomics 2010; 13(5): 310-319.

Clinical and public health implications of emerging genetic technologies - Laberge AM, Burke W. Clinical and public health implications of emerging genetic technologies. Semin Nephrol 2010; 30(2): 185-194.

Debating clinical utility - Burke W, Laberge AM, Press N. Debating clinical utility. Pub Health Genomics 2010; 13(4): 215-223.

Duty to warn family members of familial genetic risk - Laberge AM, Burke W. Duty to warn family members of familial genetic risk. Virtual Mentor. American Medical Association Journal of Ethics 2009; 11: 656-660.

Long-term outcomes of the "Genetics in Primary Care" faculty development initiative - Laberge AM, Fryer-Edwards K, Kyler P, Lloyd-Puryear MA, Burke W. Long-term outcomes of the "Genetics in Primary Care" faculty development initiative. Fam Med 2009; 41(4): 266-270.

Use of Factor V Leiden genetic testing in practice and impact on management - Laberge AM, Psaty BM, Hindorff LA, Burke W. Use of Factor V Leiden genetic testing in practice and impact on management. Genet Med 2009; 11(10): 750-756.

Motivating factors for physician ordering of factor V Leiden genetic tests - Hindorff LA, Burke W, Laberge AM, Rice KM, Lumley T, Leppig K, Rosendaal FR, Larson EB, Psaty BM. Motivating factors for physician ordering of factor V Leiden genetic tests. Arch Intern Med 2009; 169(1): 68-74.

Personalized medicine and genomics - Laberge AM, Burke W. Personalized medicine and genomics. Dans: From Birth to Death and Bench to Clinic: The Hastings Center Bioethics Briefing Book for Journalists, Policymakers, and Campaigns. Garrison (NY). The Hastings Center, 2008; 133-136.

A "Fille du Roy" Introduced the T14484C Leber Hereditary Optic Neuropathy Mutation in French Canadians - Laberge AM, Jomphe M, Houde L, Vézina H, Tremblay M, Desjardins B, Labuda D, St-Hilaire M, Macmillan C, Shoubridge EA, Brais B. A "Fille du Roy" Introduced the T14484C Leber Hereditary Optic Neuropathy Mutation in French Canadians. Am J Hum Genet 2005; 77(2): 313-317.

Population history and its impact on medical genetics in Quebec - Laberge AM, Michaud JL, Richter A, Lemyre E, Lambert MA, Brais B, Mitchell GA. Population history and its impact on medical genetics in Quebec. Clin Genet 2005; 68(4): 287-301.

About this page
Edited by Hoffmann-Belisle, Maude
Updated on 7/2/2015
Created on 9/18/2014
Alert or send a suggestion

Every dollar counts!

Thank you for your generosity.

It's people like you that allow us to accelerate research and heal more children better every year and, as such, offer among the best healthcare in the world.

It's also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine